Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions

Journal of Urology

Volumn 185, Issue 6, 2011, Pages 2119-2125

  De La Taille, Alexandre ^a   Irani, Jacques ^b   Graefen, Markus ^c   Chun, Felix ^c   De Reijke, Theo ^d   Kil, Paul ^e   Gontero, Paolo ^f   Mottaz, Alain ^g   Haese, Alexander ^c  

^a HENRI MONDOR HOSPITAL   (France)

^b POITIERS UNIVERSITY HOSPITAL   (France)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d ACADEMIC MEDICAL CENTER   (Netherlands)

^e Microvida Laboratory for Medical Microbiology and Immunology   (Netherlands)

^f UNIVERSITY OF TURIN   (Italy)

^g Gene Predictis SA   (Switzerland)

Author keywords

biopsy; human; prostate cancer antigen 3; prostate specific antigen; prostatic neoplasms; sensitivity and specificity

Indexed keywords

PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ARTICLE; CLINICAL EVALUATION; DIAGNOSTIC ACCURACY; DIGITAL RECTAL EXAMINATION; DRUG SCREENING; GLEASON SCORE; HUMAN; INSTRUMENTATION; MAJOR CLINICAL STUDY; MALE; MEDICAL DECISION MAKING; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROSTATE BIOPSY; PROSTATE CANCER; PROSTATE CANCER GENE 3 ASSAY; SCORING SYSTEM; SENSITIVITY AND SPECIFICITY; TUMOR GENE; URINALYSIS;

AGED; ANTIGENS, NEOPLASM; BIOPSY; HUMANS; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PROSPECTIVE STUDIES; PROSTATE; PROSTATIC NEOPLASMS;

EID: 79955872382     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.juro.2011.01.075     Document Type: Article

References (27)

1. B. Tombal Over- and underdiagnosis of prostate cancer: the dangers Eur Urol Suppl 5 2006 511
2. I.M. Thompson, D.K. Pauler, and P.J. Goodman Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter N Engl J Med 350 2004 2239
3. R. Postma, and F.H. Schrder Screening for prostate cancer Eur J Cancer 41 2005 825
4. J.C. Presti Jr, G.J. O'Dowd, and M.C. Miller Extended peripheral zone biopsy schemes increase cancer detection rates and minimize variance in prostate specific antigen and age related cancer rates: results of a community multi-practice study J Urol 169 2003 125
5. C. Seitz, S. Palermo, and B. Djavan Prostate biopsy Minerva Urol Nefrol 55 2003 205
6. J. Raja, N. Ramachandran, and G. Munneke Current status of transrectal ultrasound-guided prostate biopsy in the diagnosis of prostate cancer Clin Radiol 61 2006 142
7. E. zden, Y. Bostanci, and K.Y. Yakupoglu Incidence of acute prostatitis caused by extended-spectrum β-lactamase-producing escherichia coli after transrectal prostate biopsy Urology 74 2009 119
8. R. Raaijmakers, W.J. Kirkels, and M.J. Roobol Complication rates and risk factors of 5802 transrectal ultrasound-guided sextant biopsies of the prostate within a population-based screening program Urology 60 2002 826
9. L.S. Marks, Y. Fradet, and I.L. Deras PCA3 molecular urine assay for prostate cancer in men undergoing repeat biopsy Urology 69 2007 532
10. A. Haese, A. de laTaille, and H. Van Poppel Clinical utility of the PCA3 urine assay in European men scheduled for repeat biopsy Eur Urol 54 2008 1081
11. I.L. Deras, S.M. Aubin, and A. Blase PCA3: a molecular urine assay for predicting prostate biopsy outcome J Urol 179 2008 1587
12. H. Nakanishi, J. Groskopf, and H.A. Fritsche PCA3 molecular urine assay correlates with prostate cancer tumor volume: implication in selecting candidates for active surveillance J Urol 179 2008 1804
13. E.J. Whitman, J. Groskopf, and A. Ali PCA3 score before radical prostatectomy predicts extracapsular extension and tumor volume J Urol 180 2008 1975
14. Product package insert for PROGENSA PCA3 Assay.
15. J.I. Epstein, P.C. Walsh, and M. Carmichael Pathologic and clinical findings to predict tumor extent of nonpalpable (stage T1c) prostate cancer JAMA 271 1994 368
16. P.J. Bastian, L.A. Mangold, and J.I. Epstein Characteristics of insignificant clinical T1c prostate tumors A contemporary analysis Cancer 101 2004 2001
17. M.P. van Gils, D. Hessels, and C.A. Hulsbergen-van de Kaa Detailed analysis of histopathological parameters in radical prostatectomy specimens and PCA3 urine test results Prostate 68 2008 1215
18. J.J. Tosoian, S. Loeb, and A. Kettermann Accuracy of PCA3 measurement in predicting short-term biopsy progression in an active surveillance program J Urol 183 2010 534
19. D. Hessels, M.P. van Gils, and O. van Hooij Predictive value of PCA3 in urinary sediments in determining clinico-pathological characteristics of prostate cancer Prostate 70 2010 10
20. F.K. Chun, A. de laTaille, and H. Van Poppel Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram Eur Urol 56 2009 659
21. M.W. Kattan Evaluating a new marker's predictive contribution Clin Cancer Res 10 2004 822
22. M.W. Kattan Judging new markers by their ability to improve predictive accuracy J Natl Cancer Inst 95 2003 634
23. Prostate Cancer Prevention Trial risk calculator http://deb.uthscsa.edu/ URORiskCalc/Pages/calcsPCA3.jsp Accessed April 2010
24. J.C. Presti Prostate biopsy: current status and limitations Rev Urol 9 2007 93
25. S. Egawa, K. Suyama, and R. Takashima Probability of prostate cancer at various levels of per cent free prostate specific antigen in Japanese men with total PSA of 4.1-10.0 ng/ml Prostate Cancer Prostatic Dis 5 2002 115
26. C.H. Bangma, J.B. Rietbergen, and R. Kranse The free-to-total prostate specific antigen ratio improves the specificity of prostate specific antigen in screening for prostate cancer in the general population J Urol 157 1997 2191
27. J. Groskopf, S.M. Aubin, and I.L. Deras APTIMA PCA3 molecular urine test: development of a method to aid in the diagnosis of prostate cancer Clin Chem 52 2006 1089